# Customized Choice of Oral P2Y12 Receptor Blocker

Study · id `cardio:ct-nct01477775` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01477775](<https://clinicaltrials.gov/study/NCT01477775>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01477775

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4000 participants.

## Technical summary

Registry record NCT01477775. Randomized; no masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 4000 participants (planned count; ClinicalTrials.gov record NCT01477775, source copy `cardio:ctgov-nct01477775-2014-09-03`, retrieved 2026-10-26)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01477775, source copy `cardio:ctgov-nct01477775-2014-09-03`, retrieved 2026-10-26)
- Primary completion: 2014-12 (anticipated) (ClinicalTrials.gov record NCT01477775, source copy `cardio:ctgov-nct01477775-2014-09-03`, retrieved 2026-10-26)
- Completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01477775, source copy `cardio:ctgov-nct01477775-2014-09-03`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01477775, source copy `cardio:ctgov-nct01477775-2014-09-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01477775-2014-09-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Customized Choice of Oral P2Y12 Receptor Blocker
- Acronym: PRU-MATRIX
- Condition: Acute Coronary Syndrome
- Condition: Coronary Angioplasty
- Intervention (Drug): Oral P2Y12 receptor blocker
- Intervention (Drug): Customized choice for the oral P2Y12 receptor blocker
- Lead sponsor: Italian Society of Invasive Cardiology
- Lead sponsor class: OTHER
- Collaborator: Eustrategy
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Italian Society of Invasive Cardiology (`cardio:org-italian-society-of-invasive-cardiology`)

## Provenance

Content hash: 3b6aff832529d029fb758f8c21842871766c2b6deb0e89ce1c298bac3bf4085f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
